Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

A Study to Investigate the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants.Completed
NCT06979388Phase 1Updated Aug 12, 2025
Sponsor: AstraZeneca
Healthy Participants
United Kingdom
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast CancerRecruiting
NCT03740893Phase 2Updated Aug 11, 2025
Sponsor: Institute of Cancer Research, United Kingdom
Breast Neoplasm · Triple Negative Breast Cancer (TNBC) · HRD
United Kingdom
Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRIActive Not Recruiting
NCT03733535NAUpdated Aug 11, 2025
Sponsor: Dr. Grace Parraga
Asthma; Eosinophilic
Canada
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen LoadTerminated
NCT04336943Phase 2Updated Aug 11, 2025
Sponsor: University of Washington
Biochemically Recurrent Prostate Carcinoma · Prostate Adenocarcinoma
United States
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)Active Not Recruiting
NCT04136171Phase 3Updated Aug 8, 2025
Sponsor: Ionis Pharmaceuticals, Inc.
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
United States, Argentina, Australia, Austria, Belgium +16 more
An Observational Prospective Cohort Study for Long-term Management of Hyperkalemia in Patients With Chronic Kidney Disease or Heart FailureCompleted
NCT05297409N/AUpdated Aug 8, 2025
Sponsor: AstraZeneca
Hyperkalemia
Japan
Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial.Completed
NCT03623646Phase 2Updated Aug 8, 2025
Sponsor: Institut Claudius Regaud
Oropharyngeal Squamous Cell Carcinoma
France
MEDI5752 in Japanese Patients With Advanced Solid Tumors.Completed
NCT05685472Phase 1Updated Aug 8, 2025
Sponsor: AstraZeneca
Advanced Solid Tumors
Japan
EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)Completed
NCT06742736N/AUpdated Aug 7, 2025
Sponsor: AstraZeneca
Pulmonary Disease, Chronic Obstructive
United States
A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast CancerCompleted
NCT04541433Phase 1Updated Aug 7, 2025
Sponsor: AstraZeneca
ER+ HER2- Advanced Breast Cancer
Japan
Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102)Recruiting
NCT05885009N/AUpdated Aug 6, 2025
Sponsor: SOLTI Breast Cancer Research Group
Metastatic Prostate Cancer
Spain
A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy VolunteersCompleted
NCT06348355Phase 1Updated Aug 6, 2025
Sponsor: AstraZeneca
Healthy Volunteers
Sweden
Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE)Active Not Recruiting
NCT05049044N/AUpdated Aug 4, 2025
Sponsor: Groupe Francais De Pneumo-Cancerologie
Non-Small Cell Lung Cancer
France
Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid TumoursUnknown
NCT02223923Phase 1Updated Aug 1, 2025
Sponsor: Royal Marsden NHS Foundation Trust
Solid Tumour Refractory to Conventional Treatment
United Kingdom
Phase 1 Trial of AZD6422 in CLDN18.2+ GI TumorsCompleted
NCT05981235Phase 1Updated Jul 31, 2025
Sponsor: Peking University
Gastrointestinal Tumors
China
A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral FormulationsCompleted
NCT06996886Phase 1Updated Jul 31, 2025
Sponsor: AstraZeneca
Healthy Participants
United States
Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic SarcomaActive Not Recruiting
NCT05821231Phase 1Updated Jul 31, 2025
Sponsor: Institut Claudius Regaud
Soft Tissue Sarcoma
France
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 InhibitionActive Not Recruiting
NCT05061134Phase 2Updated Jul 31, 2025
Sponsor: AstraZeneca
Melanoma
United States, Australia, Belgium, Canada, France +6 more
Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer PatientsCompleted
NCT04353973NAUpdated Jul 29, 2025
Sponsor: Abramson Cancer Center at Penn Medicine
Cancer
United States
A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With QuinidineCompleted
NCT06974565Phase 1Updated Jul 25, 2025
Sponsor: AstraZeneca
Advanced Chronic Liver Disease · Healthy Participants
United States
Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status.Active Not Recruiting
NCT04348045Phase 2Updated Jul 25, 2025
Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
Metastatic Pancreatic Adenocarcinoma
France
A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy ParticipantsCompleted
NCT06973005Phase 1Updated Jul 24, 2025
Sponsor: AstraZeneca
Advanced Chronic Liver Disease · Healthy Participants
United States
SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With PrediabetesRecruiting
NCT06054035Phase 4Updated Jul 24, 2025
Sponsor: University Hospital Tuebingen
Type2diabetes · PreDiabetes · Renal Failure
Germany
A Study to Evaluate the Consistency of Oscillometry and Spirometry Test Results in Patients With Confirmed or Suspected Asthma or COPDCompleted
NCT06172777N/AUpdated Jul 24, 2025
Sponsor: AstraZeneca
Asthma/ COPD
China
Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.Active Not Recruiting
NCT03704480Phase 2Updated Jul 23, 2025
Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
Advanced Biliary Tract Carcinoma
France

Previous page Next page